Title of article - Human Cancer Immunotherapy with PD-1/PD-L1 Blockade.
Abstract
The ligation of programmed cell death-1 (PD-1) to its ligands PD-L1 and PD-L2 counteracts T-cell activation, which is critical in immune tolerance. The persistent high expression of PD-1 and PD-L1 are also observed on tumor-infiltrating lymphocytes and various tumor cells, maintaining the highly suppressive microenvironment in tumor sites and promoting tumor malignancies. The blockade of PD-1 axis with PD-L2 fusion protein or monoclonal antibodies against either PD-1 or PD-L1 has been clinically evaluated in various tumor types. This short review summarizes the progress of PD-1 axis blockade in clinical trials to evaluate its effectiveness in the antitumor immunotherapy.
CLICK HERE for Full article Click button above to go to original article link with complete article details for Human Cancer Immunotherapy with PD-1/PD-L1 Blockade.
Please CLICK HERE to discuss with us on facebook about this article.
Click below for Details of research Institute
Institute of Metabolism and Endocrinology, The Second Xiangya Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China.
Details of Journal for Human Cancer Immunotherapy with PD-1/PD-L1 Blockade.
Journal Title - Biomarkers in cancer
ISSN - 1179-299X
Volume - 7
Issue - 0
Publish date - 2015-
Language - eng
Country - New Zealand
No comments:
Post a Comment